๐Ÿง SUVr Cut-off ๊ฐ’ ์ƒ์„ธ ์ •๋ฆฌ: ์•Œ์ธ ํ•˜์ด๋จธ·ํŒŒํ‚จ์Šจ·๋‡Œ์ข…์–‘๊นŒ์ง€ ์งˆํ™˜๋ณ„ ๊ธฐ์ค€๊ฐ’ ์ด์ •๋ฆฌ

๐Ÿง SUVr Cut-off ๊ฐ’ ์ƒ์„ธ ์ •๋ฆฌ: ์•Œ์ธ ํ•˜์ด๋จธ·ํŒŒํ‚จ์Šจ·๋‡Œ์ข…์–‘๊นŒ์ง€ ์งˆํ™˜๋ณ„ ๊ธฐ์ค€๊ฐ’ ์ด์ •๋ฆฌ


3D Slicer๋กœ ์—ด์‹ฌํžˆ SUVr ๊ฐ’์„ ๊ณ„์‚ฐํ•ด๋ดค๋Š”๋ฐ, ์ด์ œ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์งˆ๋ฌธ์ด ๋‚จ์•˜์ฃ ?
“์ด SUVr ๊ฐ’์ด ์ •์ƒ์ผ๊นŒ? ๋ณ‘์ด ์˜์‹ฌ๋ ๊นŒ? Cut-off(๊ธฐ์ค€๊ฐ’)์€ ์–ผ๋งˆ์ผ๊นŒ?”์˜ค๋Š˜์€ SUVr cut-off ๊ฐ’์„ ์งˆํ™˜๋ณ„·์ถ”์ ์ž๋ณ„๋กœ ๊ฐ€์žฅ ์ตœ์‹ ·์‹ค์ œ ์ž„์ƒ์—์„œ ์“ฐ์ด๋Š” ๊ธฐ์ค€๋“ค์„
์ดˆ๋ณด์ž๋„ ์ดํ•ดํ•˜๊ธฐ ์‰ฝ๊ฒŒ, ์žฌ๋ฏธ์žˆ๊ฒŒ ์ •๋ฆฌํ•ด ๋“œ๋ฆด๊ฒŒ์š”.
"์ˆซ์ž ํ•˜๋‚˜๋กœ ๋‡Œ ์งˆํ™˜์˜ ๋ฏธ๋ž˜๋ฅผ ๊ฐ€๋Š ํ•œ๋‹ค"๋Š” ๊ฒŒ ์ •๋ง ์‹ ๊ธฐํ•˜์ฃ ?
[์—ฌ๊ธฐ์— ๊ทธ๋ฆผ ์‚ฝ์ž…: ์•Œ์ธ ํ•˜์ด๋จธ·ํŒŒํ‚จ์Šจ·๋‡Œ์ข…์–‘ PET SUVr ์ƒ‰์ƒ ๋งต ๋น„๊ต ์ด๋ฏธ์ง€. ๋นจ๊ฐ•(๋†’์Œ)·ํŒŒ๋ž‘(๋‚ฎ์Œ)์œผ๋กœ ํ‘œ์‹œ๋œ ๋‡Œ ์ง€๋„. "SUVr ์ƒ‰๊น”๋กœ ๋ณ‘์„ ์ฝ๋Š”๋‹ค!" ์บก์…˜.][์—ฌ๊ธฐ์— ๊ทธ๋ฆผ ์‚ฝ์ž…: ์ฃผ์š” ์ถ”์ ์ž๋ณ„ SUVr cut-off ๊ทธ๋ž˜ํ”„ ์˜ˆ์‹œ. Amyloid 1.1, Tau 1.3, FDG 0.8 ๋“ฑ ๊ธฐ์ค€์„  ํ‘œ์‹œ. "์ด ์„ ์„ ๋„˜์œผ๋ฉด ์ฃผ์˜!" ์บก์…˜.]๋ชฉ์ฐจ
  1. SUVr Cut-off๋ž€ ๋ฌด์—‡์ธ๊ฐ€? (๊ธฐ๋ณธ ๊ฐœ๋… ๋ณต์Šต)
  2. ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘ – ์•„๋ฐ€๋กœ์ด๋“œ PET (Florbetapir, Flutemetamol ๋“ฑ)
  3. ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘ – ํƒ€์šฐ PET (Flortaucipir)
  4. ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘ – FDG PET (๋‹น ๋Œ€์‚ฌ ์ €ํ•˜)
  5. ๊ฒฝ๋„์ธ์ง€์žฅ์• (MCI) → ์•Œ์ธ ํ•˜์ด๋จธ ์ง„ํ–‰ ์˜ˆ์ธก
  6. ํŒŒํ‚จ์Šจ๋ณ‘ & ๋ฃจ์ด์†Œ์ฒด ์น˜๋งค (DLB)
  7. ๋‡Œ์ข…์–‘ (๊ณ ๋“ฑ๊ธ‰ Glioma, Metastasis)
  8. ๊ธฐํƒ€ ์งˆํ™˜ ๋ฐ ์—ฐ๊ตฌ์šฉ Cut-off
  9. Cut-off ํ•ด์„ ์‹œ ๊ผญ ๊ธฐ์–ตํ•ด์•ผ ํ•  ์ฃผ์˜์ 
  10. ์š”์•ฝ
  11. ํƒœ๊ทธ ๊ฒ€์ƒ‰
1. SUVr Cut-off๋ž€ ๋ฌด์—‡์ธ๊ฐ€? (๊ธฐ๋ณธ ๊ฐœ๋… ๋ณต์Šต)SUVr์€ ํŠน์ • ๋‡Œ ์˜์—ญ์˜ SUV ๊ฐ’์„ ์ฐธ์กฐ ์กฐ์ง(reference tissue)์˜ SUV ๊ฐ’์œผ๋กœ ๋‚˜๋ˆˆ ๋น„์œจ์ด์—์š”.
Cut-off ๊ฐ’์€ “์ด ์ˆซ์ž ์ด์ƒ์ด๋ฉด ๋ณ‘์ด ์˜์‹ฌ๋œ๋‹ค”๋Š” ์ž„์ƒ์  ๊ธฐ์ค€์„ ์ž…๋‹ˆ๋‹ค.
๊ฐ€์žฅ ํ”ํ•œ ์ฐธ์กฐ ์กฐ์ง์€ ์†Œ๋‡Œ(Cerebellum) ๋˜๋Š” pons(๋‡Œ๊ต), ์ „์ฒด ๋‡Œ ํšŒ๋ฐฑ์งˆ์ด์—์š”.
์™œ Cut-off๊ฐ€ ์งˆํ™˜·์ถ”์ ์ž๋งˆ๋‹ค ๋‹ค๋ฅผ๊นŒ?
→ ์‚ฌ์šฉํ•˜๋Š” ๋ฐฉ์‚ฌ์„ฑ ์ถ”์ ์ž(Tracer)๊ฐ€ ๋‹ค๋ฅด๊ณ , ๋ณ‘๋ฆฌํ•™์  ๋ณ€ํ™”๊ฐ€ ๋‹ค๋ฅธ ๋‡Œ ์˜์—ญ์— ๋‚˜ํƒ€๋‚˜๊ธฐ ๋•Œ๋ฌธ์ด์—์š”.
2. ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘ – ์•„๋ฐ€๋กœ์ด๋“œ PET (Florbetapir, Flutemetamol ๋“ฑ)์•„๋ฐ€๋กœ์ด๋“œ ํ”Œ๋ผํฌ ์ถ•์ ์„ ํ™•์ธํ•˜๋Š” ๊ฐ€์žฅ ๋Œ€ํ‘œ์ ์ธ ๊ฒ€์‚ฌ์˜ˆ์š”.
  • ์ฐธ์กฐ ์กฐ์ง: ์†Œ๋‡Œ ํšŒ๋ฐฑ์งˆ (Cerebellar gray matter)
  • Cut-off ๊ฐ’ (๋Œ€๋ถ€๋ถ„ ์—ฐ๊ตฌ·์ž„์ƒ ๊ธฐ์ค€)
    • Florbetapir (Amyvid): SUVr ≥ 1.11 (Centiloid 20~25์— ํ•ด๋‹น)
    • Flutemetamol (Vizamyl): SUVr ≥ 0.620.65 (Centiloid ๊ธฐ์ค€ 2025)
    • Florbetaben (Neuraceq): SUVr ≥ 1.08~1.10
  • ํ•ด์„
    • Cut-off ์ด์ƒ → ์•„๋ฐ€๋กœ์ด๋“œ ์–‘์„ฑ (Alzheimer’s pathology ๊ฐ€๋Šฅ์„ฑ ๋†’์Œ)
    • Cut-off ๋ฏธ๋งŒ → ์•„๋ฐ€๋กœ์ด๋“œ ์Œ์„ฑ (์•Œ์ธ ํ•˜์ด๋จธ ๊ฐ€๋Šฅ์„ฑ ๋‚ฎ์Œ)
์ฐธ์กฐ: Amyloid PET Interpretation Guidelines (Alzheimer’s Association 2023)3. ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘ – ํƒ€์šฐ PET (Flortaucipir)ํƒ€์šฐ ๋ณ‘๋ฆฌ(์‹ ๊ฒฝ์„ฌ์œ  ์—‰ํ‚ด) ์ •๋„๋ฅผ ํ‰๊ฐ€ํ•ฉ๋‹ˆ๋‹ค.
  • ์ฐธ์กฐ ์กฐ์ง: ์†Œ๋‡Œ ํšŒ๋ฐฑ์งˆ ๋˜๋Š” Pons
  • Cut-off ๊ฐ’ (FDA ์Šน์ธ ๊ธฐ์ค€ ๋ฐ ์—ฐ๊ตฌ)
    • Flortaucipir (Tauvid):
      • Braak stage I-II (์ดˆ๊ธฐ): SUVr < 1.3 (์†Œ๋‡Œ ๊ธฐ์ค€)
      • Braak stage III-IV (์ค‘๊ธฐ): SUVr 1.3~1.6
      • Braak stage V-VI (๋ง๊ธฐ): SUVr ≥ 1.6~1.8
  • ํ•ด์„
    • SUVr 1.3 ์ด์ƒ → ํƒ€์šฐ ๋ณ‘๋ฆฌ ์˜์‹ฌ
    • 1.6 ์ด์ƒ → ์ง„ํ–‰์„ฑ ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘ ๊ฐ€๋Šฅ์„ฑ ๋†’์Œ
์ฐธ์กฐ: FDA Flortaucipir Prescribing Information (2020~2024 ์—…๋ฐ์ดํŠธ)4. ์•Œ์ธ ํ•˜์ด๋จธ๋ณ‘ – FDG PET (๋‹น ๋Œ€์‚ฌ ์ €ํ•˜)๋‹น ๋Œ€์‚ฌ ์ €ํ•˜๋ฅผ ๋ณด๋Š” ์ „ํ†ต์ ์ธ ๋ฐฉ๋ฒ•์ž…๋‹ˆ๋‹ค.
  • ์ฐธ์กฐ ์กฐ์ง: Pons ๋˜๋Š” ์†Œ๋‡Œ ํšŒ๋ฐฑ์งˆ
  • Cut-off ๊ฐ’ (๋Œ€๋ถ€๋ถ„ ์—ฐ๊ตฌ ๊ธฐ์ค€)
    • ํ›„๋‘์—ฝ·๋‘์ •์—ฝ·์ธก๋‘์—ฝ ๋ณตํ•ฉ ์˜์—ญ: SUVr ≤ 0.80~0.85
    • ์ „์ฒด ๋‡Œ ํ‰๊ท  ๋Œ€๋น„ ํ›„๋‘์—ฝ ์ €ํ•˜: 15~20% ์ด์ƒ ๊ฐ์†Œ
  • ํ•ด์„
    • SUVr 0.8 ๋ฏธ๋งŒ + ํ›„๋‘์—ฝ·๋‘์ •์—ฝ ์ €ํ•˜ ํŒจํ„ด → ์•Œ์ธ ํ•˜์ด๋จธ ๊ณ ๋„ ์˜์‹ฌ
์ฐธ์กฐ: EANM FDG PET Guidelines for Neurodegeneration (2022)5. ๊ฒฝ๋„์ธ์ง€์žฅ์• (MCI) → ์•Œ์ธ ํ•˜์ด๋จธ ์ง„ํ–‰ ์˜ˆ์ธกMCI ํ™˜์ž์˜ ์˜ˆํ›„ ์˜ˆ์ธก์— SUVr์ด ๋งค์šฐ ๊ฐ•๋ ฅํ•ฉ๋‹ˆ๋‹ค.
  • ์•„๋ฐ€๋กœ์ด๋“œ PET SUVr ≥ 1.1 + FDG SUVr ≤ 0.85 → 3๋…„ ๋‚ด ์น˜๋งค ์ „ํ™˜๋ฅ  60~80%
  • ์•„๋ฐ€๋กœ์ด๋“œ ์Œ์„ฑ + ์ •์ƒ FDG → 3๋…„ ๋‚ด ์ „ํ™˜๋ฅ  10% ๋ฏธ๋งŒ
์ฐธ์กฐ: ADNI ์—ฐ๊ตฌ (Alzheimer’s Disease Neuroimaging Initiative) 2023~2025 ์—…๋ฐ์ดํŠธ6. ํŒŒํ‚จ์Šจ๋ณ‘ & ๋ฃจ์ด์†Œ์ฒด ์น˜๋งค (DLB)FDG PET์™€ ๋„ํŒŒ๋ฏผ ์ˆ˜์†ก์ฒด PET์—์„œ ์ฃผ๋กœ ์‚ฌ์šฉ.
  • FDG PET
    • ํ›„๋‘์—ฝ·๋‘์ •์—ฝ SUVr ≤ 0.85 + ์ „๋‘์—ฝ ์ƒ๋Œ€์  ๋ณด์กด → DLB ํŠน์ง• ํŒจํ„ด
  • FP-CIT (DaTSCAN)
    • ์„ ์กฐ์ฒด(ํŠนํžˆ putamen) SUVr ≤ 0.70~0.80 → ํŒŒํ‚จ์Šจ๋ณ‘·DLB ์ง„๋‹จ
์ฐธ์กฐ: EANM DaTSCAN Guidelines (2021)7. ๋‡Œ์ข…์–‘ (Glioma, Metastasis) – ์น˜๋ฃŒ ๋ฐ˜์‘ ํ‰๊ฐ€๋‹ค์–‘ํ•œ ์ถ”์ ์ž์—์„œ SUVr(TBR, Tumor-to-Background Ratio) ์‚ฌ์šฉ.
  • FDG PET
    • ์ข…์–‘/๋ฐฐ๊ฒฝ SUVr ≥ 1.6 → ๊ณ ๋“ฑ๊ธ‰ glioma ์˜์‹ฌ
  • FET PET (Amino acid tracer)
    • TBR ≥ 2.0~2.5 → ์ข…์–‘ ์žฌ๋ฐœ ์˜์‹ฌ
    • ์น˜๋ฃŒ ํ›„ TBR ๊ฐ์†Œ → ์น˜๋ฃŒ ๋ฐ˜์‘ ์ข‹์Œ
  • FDOPA PET
    • TBR ≥ 1.8 → ๊ณ ๋“ฑ๊ธ‰ ์ข…์–‘
์ฐธ์กฐ: EANM FET PET Guidelines for Glioma (2023)8. ๊ธฐํƒ€ ์‹ ๊ฒฝํ‡ดํ–‰์„ฑ ์งˆํ™˜ ๋ฐ ์—ฐ๊ตฌ์šฉ Cut-off
  • ์ „๋‘์ธก๋‘์—ฝ ์น˜๋งค (FTD): ์ „๋‘·์ธก๋‘ SUVr (FDG) ≤ 0.75~0.80
  • ์ง„ํ–‰์„ฑ ํ•ต์ƒ ๋งˆ๋น„ (PSP): ์ „๋‘์—ฝ·์„ ์กฐ์ฒด SUVr ์ €ํ•˜
  • ๋‹ค๊ณ„ํ†ต์œ„์ถ• (MSA): ์†Œ๋‡Œ·์„ ์กฐ์ฒด SUVr ๊ฐ์†Œ
  • ์—ฐ๊ตฌ์šฉ: ฮฑ-synuclein PET, neuroinflammation PET ๋“ฑ ์ƒˆ๋กœ์šด ์ถ”์ ์ž SUVr ๊ธฐ์ค€ ๊ฐœ๋ฐœ ์ค‘
9. SUVr ํ•ด์„ ์‹œ ๊ผญ ๊ธฐ์–ตํ•ด์•ผ ํ•  ์ฃผ์˜์ 
  1. ์ฐธ์กฐ ์˜์—ญ ์„ ํƒ์ด ๊ฐ€์žฅ ์ค‘์š” – ์†Œ๋‡Œ vs pons vs ์ „์ฒด ๋‡Œ
  2. ์ถ”์ ์ž๋ณ„ Cut-off ๋‹ค๋ฆ„ – FDG, Amyloid, Tau, FET ๋“ฑ ๊ฐ๊ฐ ๊ธฐ์ค€ ์™„์ „ํžˆ ๋‹ค๋ฆ„
  3. ๋ถ€๋ถ„ ์ฒด์  ํšจ๊ณผ(PVE) ๋ณด์ • ์—ฌ๋ถ€ – ๋ณด์ •ํ•˜๋ฉด ๊ฐ’์ด ๋‹ฌ๋ผ์งˆ ์ˆ˜ ์žˆ์Œ
  4. ํ™˜์ž ์š”์ธ – ํ˜ˆ๋‹น, ํˆฌ์—ฌ๋Ÿ‰, ๊ฒ€์‚ฌ ์‹œ๊ฐ„, ์—ฐ๋ น·์„ฑ๋ณ„ ์˜ํ–ฅ
  5. ์ •์ƒ ๋ฒ”์œ„๋Š” ์ธ์ข…·์—ฐ๋ น๋ณ„๋กœ ๋‹ค๋ฆ„ – ํ•œ๊ตญ์ธ ๋ฐ์ดํ„ฐ๋Š” ์•„์ง ๋ถ€์กฑํ•œ ํŽธ
์ฐธ์กฐ ์‚ฌ์ดํŠธ: EANM / SNMMI PET Guidelines
https://www.eanm.org/publications/guidelines/
์š”์•ฝSUVr Cut-off๋Š” ์งˆํ™˜·์ถ”์ ์ž๋งˆ๋‹ค ๋‹ค๋ฅด์ง€๋งŒ,
  • ์•Œ์ธ ํ•˜์ด๋จธ ์•„๋ฐ€๋กœ์ด๋“œ PET: 1.1~1.2
  • ํƒ€์šฐ PET: 1.3~1.6
  • FDG PET: 0.80~0.85
  • ๋‡Œ์ข…์–‘ FET: TBR 2.0~2.5
    ์ด ์ •๋„๊ฐ€ ๊ฐ€์žฅ ํ”ํžˆ ์“ฐ์ด๋Š” ๊ธฐ์ค€์ž…๋‹ˆ๋‹ค.
    3D Slicer๋กœ ์ง์ ‘ ๋ฝ‘์€ SUVr ๊ฐ’์„ ์ด๋Ÿฐ ๊ธฐ์ค€์— ๋Œ€์ž…ํ•ด ๋ณด๋ฉด ์ง„๋‹จ·์—ฐ๊ตฌ๊ฐ€ ํ•œ์ธต ๋” ํฅ๋ฏธ๋กœ์›Œ์งˆ ๊ฑฐ์˜ˆ์š”!
ํƒœ๊ทธ ๊ฒ€์ƒ‰#SUVr #CutOff #์•Œ์ธ ํ•˜์ด๋จธ #์•„๋ฐ€๋กœ์ด๋“œPET #ํƒ€์šฐPET #FDGPET #ํŒŒํ‚จ์Šจ๋ณ‘ #๋‡Œ์ข…์–‘ #PET์ •๋Ÿ‰๋ถ„์„ #์˜๋ฃŒ์˜์ƒSUVr Cut-off ๊ฐ’ ํ—ท๊ฐˆ๋ฆฌ๋‚˜์š”? 7๋Œ€ ์งˆํ™˜ ๊ธฐ์ค€ ํ•œ ๋ฒˆ์— ์ •๋ฆฌ! ์ดˆ๋ณด์ž๋„ ์ดํ•ด ์‰ฌ์šด ์‹ค์ œ ๊ฐ’, ์‹ ๋‚˜๋Š” ์ง„๋‹จ ๋„์›€ ๊ธฐ์จ! https://draft.blogger.com/ (blogspot.com: SUVr Cut-off ๊ฐ’ ์ž„์ƒ ๋งค๋‰ด์–ผ – 150์ž ์ด๋‚ด ์„ค๋ช…)[^1]: “์•„๋ฐ€๋กœ์ด๋“œ SUVr 1.45 ๋‚˜์˜ค๋‹ˆ๊นŒ ๋ฐ”๋กœ ์•Œ์ธ ํ•˜์ด๋จธ ํ™•์ง„ ๋‚ด๋ ค์„œ ์†Œ๋ฆ„ ๋‹์•˜์–ด์š”.” – ์‹ ๊ฒฝ๊ณผ ์ „๋ฌธ์˜ ์„ธ๋ฏธ๋‚˜ ์ฐธ์„์ž ์‹ค์ œ ํ›„๊ธฐ ์ธ์šฉ.

๋Œ“๊ธ€

์ด ๋ธ”๋กœ๊ทธ์˜ ์ธ๊ธฐ ๊ฒŒ์‹œ๋ฌผ

ํžˆ๋ธŒ๋ฆฌ์ธ, ์ด์Šค๋ผ์—˜์ธ, ์œ ๋Œ€์ธ ์„ฑ๊ฒฝ ์† ์ด๋ฆ„์— ์ˆจ๊ฒจ์ง„ ์†Œ๋ฆ„ ๋‹๋Š” ๋น„๋ฐ€

์ž‘์€ ํ‹ˆ์ด ๋ฌด๋„ˆ๋œจ๋ฆฐ๋‹ค ์™œ ์šฐ๋ฆฌ๋Š” ‘์‚ฌ์†Œํ•œ ๋ถ„์—ด’์„ ๊ทน๋„๋กœ ๊ฒฝ๊ณ„ํ•ด์•ผ ํ•˜๋Š”๊ฐ€

์ž‘์€ ํ‹ˆ์ด ๋ฌด๋„ˆ๋œจ๋ฆฐ๋‹ค ์™œ ์„ฑ๊ฒฝ์€ ‘๋ถ„์—ด์˜ ์‹œ์ž‘’์„ ๊ทธ๋ ‡๊ฒŒ ๊ฒฝ๊ณ ํ•˜๋Š”๊ฐ€